BHVN Biohaven
- 52.960
- +1.320+2.56%
- 53.334
- +0.374+0.71%
Biohaven News
BofA Securities Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $65
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $69
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Buy Rating on Biohaven: Breakthrough Potential With T-Alfa in SMA Treatment
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $66
Bernstein Keeps Their Buy Rating on Biohaven Ltd. (BHVN)
BofA Securities Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $65
Biohaven Is Maintained at Overweight by JP Morgan
Biohaven Analyst Ratings
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating, Announces Target Price $68
Strong Buy Rating for Biohaven Ltd. on Troriluzole's Market Potential and Robust Pipeline
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $64
BofA Securities Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $62
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Buy Rating Affirmed for Biohaven Ltd. on Promising Troriluzole SCA Program Data and Potential Market Dominance
RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)
Analysis
Price Target
No Data
No Data